Zent Named Editor-in-Chief of Leukemia Research
Thursday, March 01, 2018
Clive S. Zent, M.D., professor of Medicine in the Division of Hematology/Oncology, has taken the reins as editor-in-chief at Leukemia Research, an international journal focused on basic and applied clinical research in hematologic malignancies.
“This is an exciting leadership opportunity for the University of Rochester in the ongoing effort to improve treatment for hematological malignancies,” Zent said.
Established in 1977, Leukemia Research includes studies on cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation and therapy of hematologic malignancies.
Zent succeeds Eric J. Feldman, M.D., formerly of Weill-Cornell Medicine, as the journal’s editor, and he is the second faculty member from the University of Rochester Medical Center to hold this post. John M. Bennett, M.D., professor emeritus of Medicine, Pathology and Laboratory Medicine, also served as editor for the journal.
At Wilmot, Zent leads the lymphoma program, and his clinical expertise is in chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. His research focuses on the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL.
UR Medicine’s Wilmot Cancer Institute is the Finger Lakes region’s leader for cancer care and research. As a component of Strong Memorial Hospital, Wilmot Cancer Institute provides specialty cancer care services at the University of Rochester Medical Center and a network of locations throughout the region. The Institute also includes a team of 100 scientists who investigate many aspects of cancer, with an emphasis on how best to provide precision cancer care. To learn more, visit wilmot.urmc.edu.